Advanced glycation endproducts in ageing and Alzheimer's disease.
Accumulation of advanced glycation endproducts (AGE) in the brain is a feature of ageing and degeneration, especially in Alzheimer's disease (AD). Increased AGE levels explain many of the neuropathological and biochemical features of AD such as extensive protein crosslinking (beta-amyloid and MAP-tau), oxidative stress and neuronal cell death. Oxidative stress and AGEs initiate a positive feedback loop, where normal age-related changes develop into a pathophysiological cascade. Combined intervention using antioxidants, metal chelators, anti-inflammatory drugs and AGE-inhibitors may be a promising neuroprotective strategy.
Münch
G
G
Physiological Chemistry I, Theodor-Boveri-Institut (Biozentrum), Würzburg, Germany. muench@biozentrum.uni-wuerzburg.de
Thome
J
J
Foley
P
P
Schinzel
R
R
Riederer
P
P
D000375:Aging / Q000378:metabolism*; D000544:Alzheimer Disease / Q000378:metabolism*; D000818:Animals; D002318:Cardiovascular Diseases / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans
D017127:Glycation End Products, Advanced